ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC
A Multi-center Randomized Phase II Study of Doxorubicin Liposome Versus Epirubicin Plus Cyclophosphamide Combined With Trastuzumab and Pertuzumab(HP), Followed by Taxon Plus HP as Neoadjuvant Therapy for HER2-positive Early Breast Cancer
Sponsor: First Affiliated Hospital, Sun Yat-Sen University
This PHASE2 trial investigates Breast Cancer and Neoadjuvant Chemotherapy and is currently ongoing. First Affiliated Hospital, Sun Yat-Sen University leads this study, which shows 6 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Nov 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
-
Jan 2022 — Nov 2023 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Jan 2022 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Dec 2019 — Jan 2021 [monthly]
Recruiting PHASE2
First recorded
Jan 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- First Affiliated Hospital, Sun Yat-Sen University
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Sun Yat-sen University
For direct contact, visit the study record on ClinicalTrials.gov .